The groundbreaking rise of Viagra has firmly established as a benchmark of pharmaceutical success, but its position within the broader sector now raises questions about long-term yields . Alternative versions are undercutting exclusivity , prompting anxieties that investing in companies heavily reliant to Viagra's previous standing could be a dange